BioCentury | Feb 11, 2020
Product Development

Alzheimer’s prevention replays the same amyloid failures as the treatment setting

The Phase II/III DIAN-TU trial of Lilly’s solanezumab and Roche’s gantenerumab was always a long shot, given the previous late-stage failures of both agents in Alzheimer’s trials. Perhaps more surprising is that both compounds remain...
BC Extra | Oct 30, 2019
Company News

Amgen narrows neuro focus to inflammation

Despite early success for Amgen’s first marketed neurology product, the company will exit research and early development for neuroscience, narrowing its focus to neuroinflammation. “To compete effectively, we need to make investments in the areas...
BC Extra | Sep 14, 2019
Clinical News

One amyloid candidate left for Biogen, Eisai after axing BACE trials

Despite ending two Phase III trials of BACE inhibitor elenbecestat Friday, Biogen and Eisai have not walked away from the amyloid hypothesis of Alzheimer’s disease. The partners' Phase III trial of anti-amyloid mAb BAN2401 forges...
BC Extra | Jul 12, 2019
Clinical News

Amyloid hypothesis takes first hit in an Alzheimer’s prevention setting

With Novartis and Amgen’s decision to halt a pair of trials in presymptomatic Alzheimer’s patients Thursday, what was widely considered the only setting left for the amyloid hypothesis in the disease took a blow. Amyloid-lowering...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | May 4, 2019
Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
BC Week In Review | Dec 1, 2017
Clinical News

Amgen, Novartis start Phase II to prevent AD

In August, Novartis AG (NYSE:NVS; SIX:NOVN), Amgen Inc. (NASDAQ:AMGN) and the Banner Alzheimer’s Institute (BAI) began the Phase II Alzheimer’s Prevention Initiative (API) Generation Study 2 to evaluate CNP520 to prevent Alzheimer’s disease. The double-blind,...
BC Week In Review | Sep 12, 2016
Clinical News

CAD106: Phase II started

Novartis and Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter or...
BC Week In Review | Sep 12, 2016
Clinical News

CNP520: Phase II started

Novartis and Amgen began the double-blind, placebo-controlled, international Phase II Alzheimer’s Prevention Initiative (API) Generation Study to evaluate intramuscular CAD106 at weeks 1, 7 and 13 and quarterly thereafter or once-daily oral CNP520 for >=5...
BioCentury | Sep 14, 2015
Strategy

Mind melding

Novartis AG's third neuroscience deal of the summer checks two boxes for the pharma by sharing the risk for a BACE inhibitor program and adding another late-stage program in neurology, all without increasing the pharma's...
Items per page:
1 - 10 of 12